Rebecca Deczynski writes, "Selling in convenience stores, especially at a low price, comes with its own challenges, Miller says. “A big part of the reason why convenience has not had the urgent healthcare products that they should have is because it is expensive to sell into them and to distribute to them. The fact that we’re a public benefit company allows us to do that because we can sacrifice profit margin for our social impact.” After the launch of its EC pill in 2024, Cadence has been developing a not-yet-released over-the-counter combined estrogen and progesterone birth control pill since 2017. This month, the company donated $80,000 worth of morning-after pills to universities in states with restricted reproductive healthcare options."
Read the full article here.
